Literature DB >> 28602518

Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.

Eric Wenzler1, Matthew F Deraedt2, Amanda T Harrington3, Larry H Danizger4.   

Abstract

This study assessed the in vitro synergy between ceftazidime, aztreonam, and ceftazidime-avibactam against serine and metallo-β-lactamase (MBL)-producing pathogens via the Etest MIC:MIC ratio and Agar-Etest synergy methods. The combination of aztreonam and ceftazidime-avibactam was synergistic against all Enterobacteriaceae. None of the tested combinations were consistently synergistic against IMP-producing P. aeruginosa.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Avibactam; Aztreonam; Carbapenemase; Ceftazidime; Etest; Synergy; beta-Lactamase

Mesh：

Substances：

Year:  2017        PMID： 28602518     DOI： 10.1016/j.diagmicrobio.2017.05.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  21 in total

Review 1.  Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.

Authors:  Sara E Boyd; David M Livermore; David C Hooper; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

2.  Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.

Authors:  Cécile Emeraud; Lelia Escaut; Athénaïs Boucly; Nicolas Fortineau; Rémy A Bonnin; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.

Authors:  M Biagi; T Wu; M Lee; S Patel; D Butler; E Wenzler
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

Review 4.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

5.  Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.

Authors:  Mohamad Yasmin; Derrick E Fouts; Michael R Jacobs; Hanan Haydar; Steven H Marshall; Richard White; Roshan D'Souza; Thomas P Lodise; Daniel D Rhoads; Andrea M Hujer; Laura J Rojas; Claudia Hoyen; Federico Perez; Amy Edwards; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

6.  In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era.

Authors:  Priya Sreenivasan; Bhawna Sharma; Satinder Kaur; Sudesh Rana; Manisha Biswal; Pallab Ray; Archana Angrup
Journal:  J Antibiot (Tokyo)       Date:  2022-06-17       Impact factor: 3.424

Review 7.  NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.

Authors:  Wenjing Wu; Yu Feng; Guangmin Tang; Fu Qiao; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

Review 8.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

9.  Case Report of an Extensively Drug-Resistant Klebsiella pneumoniae Infection With Genomic Characterization of the Strain and Review of Similar Cases in the United States.

Authors:  Fiorella Krapp; Egon A Ozer; Chao Qi; Alan R Hauser
Journal:  Open Forum Infect Dis       Date:  2018-04-06       Impact factor: 3.835

Review 10.  Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.

Authors:  Maxwell J Lasko; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2020-02-07       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.